PTPRC and neuroblastoma: Although it is difficult to detect minimal residual disease (MRD) by MFC in neuroblastoma, which is among the CD45 negative non-hematopoietic neoplasms, it has been reported that initial bone marrow investigation by MFC has an important prognostic value.